Organisation overview | |
---|---|
Type | Regulatory body |
Headquarters | New Delhi, India [ ⚑ ] 28°37′56″N 77°14′08″E / 28.632309°N 77.235531°E |
Annual budget | ₹3,358 crore (US$470 million) (2021 - 2022) [1] |
Minister responsible |
|
Organisation executive |
|
Parent department | Directorate General of Health Services, Ministry of Health and Family Welfare |
Website | cdsco |
The Central Drugs Standard Control Organisation (CDSCO) is India 's national regulatory body for cosmetics, pharmaceuticals and medical devices. It serves a similar function to the European Medicines Agency of the European Union, the PMDA of Japan , the Food and Drug Administration (FDA) of the United States , and the Medicines and Healthcare products Regulatory Agency of the United Kingdom , and the State Administration for Market Regulation of China. The Indian government has announced its plan to bring all medical devices, including implants and contraceptives under a review of the Central Drugs and Standard Control Organisation (CDSCO).
Within the CDSCO, the Drug Controller General of India (DCGI) regulates pharmaceutical and medical devices and is positioning within the Ministry of Health and Family Welfare. The DCGI is advised by the Drug Technical Advisory Board (DTAB) and the Drug Consultative Committee (DCC). Divided into zonal offices, each one carries out pre-licensing and post-licensing inspections, post-market surveillance, and drug recalls (where necessary). Manufacturers who deal with the authority required to name an Authorized Indian Representative (AIR) to represent them in all dealings with the CDSCO in India.
Though the CDSCO has a good track record with the World Health Organization, it has also been accused of past collusion with independent medical experts and pharmaceutical companies. CDSCO plans to open an international office in Beijing, China.
Central Drugs Standard Control Organization has 8 divisions:
Original source: https://en.wikipedia.org/wiki/Central Drugs Standard Control Organisation.
Read more |